Who Should Get the Third Pfizer Vaccine

According to the study, organ transplant patients experienced a decreased immune response after two doses of the SARS-CoV-2 mRNA vaccine.

Many cases of severe COVID-19 infection have also been described in these patients after completing vaccination. This prompted French health authorities to recommend a third dose of the vaccine.

Doctors of the Therapeutic Clinic of the Medical School of the Athens National University. The Kapodistrias – Theodora Psaltopoulou, Panos Malandrakis, Yiannis Danasis and Thanos Dimopoulos (Rector of EKPA) – summarized the data by presenting them.

“The group of patients included 78 people with kidney transplantation, 12 – liver, 8 – lungs or heart, 3 patients with pancreas transplanted.

The first two doses were given one month apart and the third one 61 days after the second.

The time between transplantation and vaccination was 97 +/- 8 months. Glucocorticoid-induced immunosuppression was recorded in 87% of patients, calcineurin inhibitors in 79% of patients, mycophenolic acid in 63%, mTOR inhibitors in 30%, and belatacept in 12% of patients. The antibody titer was 0% before the first dose, 4% before the second, 40% before the third, and 68% 4 weeks after the third dose.

Patients who did not have antibodies were older in age and had stronger immunosuppression. In addition, none of these patients developed COVID-19 infection after the third dose of the vaccine, and no serious side effects were observed.

These studies indicate the efficacy and safety of the third dose of Pfizer vaccine in a group of transplant patients. However, care must be taken in each case, due to the patient’s predisposition to serious illness.

It is possible that a similar three-dose strategy will be applied in the future to other categories of patients receiving immunosuppressive therapy, provided that the current clinical trials are positive.

Source link

High-quality journalistic work cannot be free, otherwise it becomes dependent on the authorities or the oligarchs.
Our site is solely funded by advertising money.
Please disable your ad blocker to continue reading the news.
Best regards, editors